Paula R Pohlmann

22PUBLICATIONS
163CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyMedical devices
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Dec 09, 2025
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.

Mark Jesus M Magbanua, Nayelis A Manon, Denise M Wolf

|Nov 24, 2025
Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach.

Taiwo Adesoye, Ecaterina E Dumbrava, Kanwal P S Raghav

|Aug 27, 2025
Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit.

Camila Braganca Xavier, Clark R Andersen, JoAnn Lim

|Jun 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.

Denise M Wolf, Christina Yau, Michael Campbell

|Feb 07, 2025
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial.

Kim A Reiss, Mathew G Angelos, E Claire Dees

|Jan 31, 2025
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.

Arielle L Heeke, Andrew Elliott, Kaitlyn O'Keefe

Pageof 4

Frequent Collaborators

7 joint publications

Gillian L Hirst

6 joint publications

Laura van 't Veer

6 joint publications

Claudine Isaacs

6 joint publications

Lamorna Brown-Swigart